The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial

被引:14
|
作者
Akbar, Sheikh Mohammad Fazle [1 ]
Al Mahtab, Mamun [2 ]
Aguilar, Julio Cesar [3 ]
Yoshida, Osamu [1 ]
Khan, Sakirul [4 ]
Penton, Eduardo [3 ]
Gerardo, Guillen Nieto [3 ]
Hiasa, Yoichi [1 ]
机构
[1] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon 7910295, Japan
[2] Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Hepatol, Dhaka 1000, Bangladesh
[3] Ctr Genet Engn & Biotechnol, Havana 10600, Cuba
[4] Oita Univ, Fac Med, Dept Microbiol, Oita 8795593, Japan
关键词
chronic hepatitis B; therapeutic vaccine; HBsAg; HBcAg vaccine; NASVAC; nasal vaccine; follow-up; CORE ANTIGEN; SURFACE; CANDIDATE; CELLS; HBCAG;
D O I
10.3390/vaccines10010045
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of the present study was to assess the safety and efficacy of a therapeutic vaccine containing both HBsAg and HBcAg (NASVAC) in patients with chronic hepatitis B (CHB) three years after the end of treatment (EOT) as a follow-up of a phase III clinical trial. NASVAC was administered ten times by the nasal route and five times by subcutaneous injection. A total of 59 patients with CHB were enrolled. Adverse events were not seen in any of the patients. Out of the 59 CHB patients, 54 patients exhibited a reduction in HBV DNA, compared with their basal levels. Although all the patients had alanine transaminase (ALT) above the upper limit of normal (>42 IU/L) before the commencement of therapy, the levels of ALT were within the ULN level in 42 patients. No patient developed cirrhosis of the liver. The present study, showing the safety and efficacy of NASVAC 3 years after the EOT, is the first to report follow-up data of an immune therapeutic agent against CHB. NASVAC represents a unique drug against CHB that is safe, of finite duration, can be administered by the nasal route, is capable of reducing HBV DNA and normalizing ALT, and contains hepatic fibrosis.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
    Akbar, Sheikh Mohammad Fazle
    Al Mahtab, Mamun
    Aguilar, Julio Cesar
    Yoshida, Osamu
    Penton, Eduardo
    Gerardo, Guillen Nieto
    Hiasa, Yoichi
    PATHOGENS, 2021, 10 (11):
  • [2] Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study
    Yoshida, Osamu
    Akbar, Sheikh Mohammad Fazle
    Imai, Yusuke
    Sanada, Takahiro
    Tsukiyama-Kohara, Kyoko
    Miyazaki, Takashi
    Kamishita, Taizou
    Miyake, Teruki
    Tokumoto, Yoshio
    Hikita, Hayato
    Tsuge, Masataka
    Shimizu, Masahito
    Al Mahtab, Mamun
    Aguilar, Julio Cesar
    Guillen, Gerardo
    Kohara, Michinori
    Hiasa, Yoichi
    HEPATOLOGY RESEARCH, 2023, 53 (03) : 196 - 207
  • [3] Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial
    Wei, Lai
    Zhao, Tingting
    Zhang, Ji
    Mao, Qing
    Gong, Guozhong
    Sun, Yongtao
    Chen, Yongping
    Wang, Maorong
    Tan, Deming
    Gong, Zuojiong
    Li, Baosen
    Niu, Junqi
    Li, Shuchen
    Gong, Huanyu
    Zou, Liyun
    Zhou, Wei
    Jia, Zhengcai
    Tang, Yan
    Fei, Lei
    Hu, Yang
    Shang, Xiaoyun
    Han, Junfeng
    Zhang, Bei
    Wu, Yuzhang
    HEPATOLOGY, 2022, 75 (01) : 182 - 195
  • [4] Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up
    Taheri, Hassan
    Roushan, Mohammad Reza Hasanjani
    Amiri, Mohammad Jafar Soleimani
    Pouralijan, Mohammad
    Bijani, Ali
    HEPATITIS MONTHLY, 2011, 11 (02) : 119 - 122
  • [5] Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)
    Al Mahtab, Mamun
    Akbar, Sheikh Mohammad Fazle
    Aguilar, Julio Cesar
    Guillen, Gerardo
    Penton, Euduaro
    Tuero, Angela
    Yoshida, Osamu
    Hiasa, Yoichi
    Onji, Morikazu
    PLOS ONE, 2018, 13 (08):
  • [6] Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
    Al Mahtab, Mamun
    Akbar, Sheikh Mohammad Fazle
    Aguilar, Julio Cesar
    Yoshida, Osamu
    Khan, Sakirul
    Gerardo, Guillen Nieto
    Hiasa, Yoichi
    FRONTIERS IN MEDICINE, 2023, 10
  • [7] Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings
    Xu, Dao-Zhen
    Wang, Xuan-Yi
    Shen, Xin-Liang
    Gong, Guo-Zhong
    Ren, Hong
    Guo, Li-Min
    Sun, Ai-Min
    Xu, Min
    Li, Lan-Juan
    Guo, Xin-Hui
    Zhen, Zhen
    Wang, Hui-Fen
    Gong, Huan-Yu
    Xu, Cheng
    Jiang, Nan
    Pan, Chen
    Gong, Zuo-Jiong
    Zhang, Ji-Ming
    Shang, Jia
    Xu, Jie
    Xie, Qing
    Wu, Tie-Feng
    Huang, Wen-Xiang
    Li, Yong-Guo
    Xu, Jing
    Yuan, Zheng-Hong
    Wang, Bin
    Zhao, Kai
    Wen, Yu-Mei
    Team, Yic Efficacy Trial Study
    JOURNAL OF HEPATOLOGY, 2013, 59 (03) : 450 - 456
  • [8] Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B A long-term follow-up cohort study from China
    Hu, Yao
    Ye, Yingzi
    Ye, Lijing
    Wang, Xiaohong
    Yu, Hui
    MEDICINE, 2019, 98 (32)
  • [9] The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
    Harper, Diane M.
    Nieminen, Pekka
    Donders, Gilbert
    Einstein, Mark H.
    Garcia, Francisco
    Huh, Warner K.
    Stoler, Mark H.
    Glavini, Katerina
    Attley, Gemma
    Limacher, Jean-Marc
    Bastien, Berangere
    Calleja, Elizabeth
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 521 - 529
  • [10] Long Term Follow-Up, Treatment and Prognosis of Chronic Hepatitis B Patients in Childhood
    Canpolat, Mehmet
    Arslan, Duran
    Soyuer, Isin
    ERCIYES MEDICAL JOURNAL, 2013, 35 (01) : 6 - 12